000276151 001__ 276151
000276151 005__ 20250209000709.0
000276151 0247_ $$2doi$$a10.3389/fnins.2024.1505999
000276151 0247_ $$2pmid$$apmid:39834700
000276151 0247_ $$2pmc$$apmc:PMC11744071
000276151 0247_ $$2ISSN$$a1662-4548
000276151 0247_ $$2ISSN$$a1662-453X
000276151 0247_ $$2altmetric$$aaltmetric:173200005
000276151 037__ $$aDZNE-2025-00223
000276151 041__ $$aEnglish
000276151 082__ $$a610
000276151 1001_ $$0P:(DE-2719)9001249$$aWagemann, Olivia$$b0$$eFirst author$$udzne
000276151 245__ $$aFeasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer's disease: a case series.
000276151 260__ $$aLausanne$$bFrontiers Research Foundation$$c2025
000276151 3367_ $$2DRIVER$$aarticle
000276151 3367_ $$2DataCite$$aOutput Types/Journal article
000276151 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738668857_12998
000276151 3367_ $$2BibTeX$$aARTICLE
000276151 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276151 3367_ $$00$$2EndNote$$aJournal Article
000276151 520__ $$aAdults with Down Syndrome (DS) have a substantially increased risk for Alzheimer's disease (AD) due to the triplicated amyloid-precursor-protein gene on chromosome 21, resulting in amyloid and tau accumulation. However, tau PET assessments are not sufficiently implemented in DS-AD research or clinical work-up, and second-generation tau tracers such as [18F]PI-2620 have not been thoroughly characterized in adults with DS. We aim at illustrating feasibility and potential diagnostic value of tau PET imaging with [18F]PI-2620 for the diagnosis of DS-AD.Five adults with DS (40% female, aged 43-62) and cognitive decline underwent clinical assessments, neuropsychological testing, lumbar puncture and multimodal neuroimaging. All underwent [18F]PI-2620 tau PET. Visual read of tau PET scans was performed by three blinded raters, assessing increased tracer uptake in brain areas corresponding to the six Braak stage regions and basal ganglia.Visual read of tau burden revealed three tau-positive individuals which corresponded to their clinical decline while two cognitively stable individuals were rated as negative. Rating showed high inter-rater reliability for all Braak stages.Tau PET imaging is a feasible and important biomarker assessment in the differential diagnosis of cognitive decline in adults with DS at risk of developing AD.
000276151 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000276151 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x1
000276151 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000276151 650_7 $$2Other$$a18F-PI-2620
000276151 650_7 $$2Other$$aAlzheimer
000276151 650_7 $$2Other$$acase series
000276151 650_7 $$2Other$$adown syndrome
000276151 650_7 $$2Other$$atau PET
000276151 650_7 $$2Other$$atrisomy 21
000276151 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b1$$udzne
000276151 7001_ $$aFranzmeier, Nicolai$$b2
000276151 7001_ $$0P:(DE-2719)9001761$$aNübling, Georg$$b3$$udzne
000276151 7001_ $$0P:(DE-2719)9001652$$aGnoerich, Johannes$$b4$$udzne
000276151 7001_ $$aZaganjori, Mirlind$$b5
000276151 7001_ $$0P:(DE-2719)9001508$$aPrix, Catharina$$b6$$udzne
000276151 7001_ $$0P:(DE-2719)9002610$$aStockbauer, Anna$$b7$$udzne
000276151 7001_ $$aWlasich, Elisabeth$$b8
000276151 7001_ $$aLoosli, Sandra V$$b9
000276151 7001_ $$aSandkühler, Katja$$b10
000276151 7001_ $$aFrontzkowski, Lukas$$b11
000276151 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b12$$udzne
000276151 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b13$$eLast author$$udzne
000276151 773__ $$0PERI:(DE-600)2411902-7$$a10.3389/fnins.2024.1505999$$gVol. 18, p. 1505999$$p1505999$$tFrontiers in neuroscience$$v18$$x1662-4548$$y2025
000276151 8564_ $$uhttps://pub.dzne.de/record/276151/files/DZNE-2025-00223.pdf$$yOpenAccess
000276151 8564_ $$uhttps://pub.dzne.de/record/276151/files/DZNE-2025-00223.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000276151 909CO $$ooai:pub.dzne.de:276151$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000276151 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001249$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000276151 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001539$$aExternal Institute$$b1$$kExtern
000276151 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001761$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000276151 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001652$$aExternal Institute$$b4$$kExtern
000276151 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001508$$aExternal Institute$$b6$$kExtern
000276151 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002610$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000276151 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000276151 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000276151 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000276151 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x1
000276151 9141_ $$y2025
000276151 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000276151 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000276151 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-11
000276151 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-11
000276151 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000276151 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT NEUROSCI-SWITZ : 2022$$d2024-12-11
000276151 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-11-09T08:11:26Z
000276151 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-11-09T08:11:26Z
000276151 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000276151 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-11
000276151 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000276151 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-11
000276151 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000276151 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-11-09T08:11:26Z
000276151 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-11
000276151 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000276151 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
000276151 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000276151 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000276151 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x1
000276151 9201_ $$0I:(DE-2719)1110008$$kAG Simons$$lMolecular Neurobiology$$x2
000276151 980__ $$ajournal
000276151 980__ $$aVDB
000276151 980__ $$aUNRESTRICTED
000276151 980__ $$aI:(DE-2719)1111015
000276151 980__ $$aI:(DE-2719)1111016
000276151 980__ $$aI:(DE-2719)1110008
000276151 9801_ $$aFullTexts